Karel Allegaert

Prof. Dr. Karel Allegaert

KU Leuven department of development and regeneration
+2
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2007 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
JJJ. Jani
J. Jani
KNKypros Herodotos Nicolaides
Kypros Herodotos Nicolaides
RKR. L. Keller
R. L. Keller
ABA. Benachi
A. Benachi
CPC. F. A. Peralta
C. F. A. Peralta
OGon behalf of the Antenatal‐CDH‐Registry Group
on behalf of the Antenatal‐CDH‐Registry Group
Objective: To assess the value of antenatally determined observed to expected fetal lung area to head circumference ratio (LHR) in the prediction of postnatal survival in isolated, congenital diaphragmatic hernia (CDH).Methods: Two groups of fetuses were examined. The first group included 650 normal fetuses at 12–32 weeks' gestation, and the data collected were used to establish a normal range of observed to expected LHR with gestational age. The second group included the data of a retrospective multicenter study of 354 fetuses with isolated CDH in which the LHR was measured on one occasion at 18–38 weeks' gestation. The patients were divided into those with left‐sided CDH with and without intrathoracic herniation of the liver and right‐sided CDH. Regression analysis was used to determine the significant predictors of postnatal survival.Results: In both the normal fetuses and those with CDH the LHR increased but the observed to expected LHR did not change significantly with gestational age. In normal fetuses the mean observed to expected LHR in the left lung was 100% (95% CI, 61–139%) and in the right lung it was 100% (95% CI, 67–133%). In fetuses with CDH the mean observed to expected LHR was 39% (range 7–79%). Regression analysis demonstrated that significant predictors of survival were the observed to expected LHR (odds ratio (OR) 1.09, 95% CI, 1.06–1.12), side of CDH (left side OR 11.14, 95% CI, 3.41–36.39) and gestational age at delivery (OR 1.18, 95% CI, 1.02–1.36).Conclusion: In CDH, the LHR increases while observed to expected LHR is independent of gestational age. In fetuses with both left‐ and right‐sided CDH, measurement of the observed to expected LHR provides a useful prediction of subsequent survival. Copyright © 2007 ISUOG. Published by John Wiley & Sons, Ltd.

1 July 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
Zahari VinarovZahari Vinarov
Zahari Vinarov
MAMohammad Abdallah
Mohammad Abdallah
JAJosé A.G. Agundez
José A.G. Agundez
Karel AllegaertKarel Allegaert
Karel Allegaert
ABAbdul W. Basit
Abdul W. Basit
PAPatrick Augustijns
Patrick Augustijns
The absorption of oral drugs is frequently plagued by significant variability with potentially serious therapeutic consequences. The source of variability can be traced back to interindividual variability in physiology, differences in special populations (age- and disease-dependent), drug and formulation properties, or food-drug interactions. Clinical evidence for the impact of some of these factors on drug pharmacokinetic variability is mounting: e.g. gastric pH and emptying time, small intestinal fluid properties, differences in pediatrics and the elderly, and surgical changes in gastrointestinal anatomy. However, the link of colonic factors variability (transit time, fluid composition, microbiome), sex differences (male vs. female) and gut-related diseases (chronic constipation, anorexia and cachexia) to drug absorption variability has not been firmly established yet. At the same time, a way to decrease oral drug pharmacokinetic variability is provided by the pharmaceutical industry: clinical evidence suggests that formulation approaches employed during drug development can decrease the variability in oral exposure. This review outlines the main drivers of oral drug exposure variability and potential approaches to overcome them, while highlighting existing knowledge gaps and guiding future studies in this area.

24 September 2018 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
Johannes Van den AnkerJohannes Van den Anker
Johannes Van den Anker
MRMichael D. Reed
Michael D. Reed
Karel AllegaertKarel Allegaert
Karel Allegaert
GKGregory L. Kearns
Gregory L. Kearns
Effective drug therapy to optimally influence disease requires an understanding of a drug's pharmacokinetic, pharmacodynamic, and pharmacogenomic interrelationships. In pediatrics, age is a continuum that can and does add variability in drug disposition and effect. This article addresses the many important factors that influence drug disposition and effect relative to age. What is known about the influence of maturation on the processes of drug absorption, distribution, metabolism, excretion, and drug receptor dynamics are outlined. Our state of understanding of many of these factors remains in flux, however, and only with additional study will we be able to better anticipate and model drug‐response relationships across the age continuum. Being able to continuously improve our care of the ill pediatric patient while simultaneously being able to accurately determine the utility of new drugs and chemical entities in this population requires our enhanced understanding of these disposition characteristics.

27 October 2010 in Neonatology
Verified
Journal Article
Closed access
PDF file
IRI. Reiss
I. Reiss
TST. Schaible
T. Schaible
LHL. van Den Hout
L. van Den Hout
ICI. Capolupo
I. Capolupo
Karel AllegaertKarel Allegaert
Karel Allegaert
FCfor the CDH EURO consortium
for the CDH EURO consortium
Congenital diaphragmatic hernia (CDH) is associated with high mortality and morbidity. To date, there are no standardized protocols for the treatment of infants with this anomaly. However, protocols based on the literature and expert opinion might improve outcome. This paper is a consensus statement from the CDH EURO Consortium prepared with the aim of achieving standardized postnatal treatment in European countries. During a consensus meeting between high-volume centers with expertise in the treatment of CDH in Europe (CDH EURO Consortium), the most recent literature on CDH was discussed. Thereafter, 5 experts graded the studies according to the Scottish Intercollegiate Guidelines Network (SIGN) Criteria. Differences in opinion were discussed until full consensus was reached. The final consensus statement, therefore, represents the opinion of all consortium members. Multicenter randomized controlled trials on CDH are lacking. Use of a standardized protocol, however, may contribute to more valid comparisons of patient data in multicenter studies and identification of areas for further research.

1 July 2013 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
THTitia Hompes
Titia Hompes
BIBenedetta Izzi
Benedetta Izzi
EGEdith Gellens
Edith Gellens
MMMaarten Morreels
Maarten Morreels
SFSteffen Fieuws
Steffen Fieuws
SCStephan Claes
Stephan Claes

23 September 2010 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
EWE. D. Wildschut
E. D. Wildschut
MAM. J. Ahsman
M. J. Ahsman
Karel AllegaertKarel Allegaert
Karel Allegaert
RMR. A. A. Mathot
R. A. A. Mathot
DTD. Tibboel
D. Tibboel
Purpose The aim of this in vitro study was to evaluate potential determinants of drug loss in different ECMO circuits. Methods Midazolam, morphine, fentanyl, paracetamol, cefazolin, meropenem and vancomycin were injected into three neonatal roller pump, two paediatric roller pump and two clinically used neonatal roller pump circuits, all with a silicone membrane, and two neonatal centrifugal pump circuits with polypropylene hollow-fibre membranes. Serial blood samples were taken from a post-oxygenator site. Drug recovery was calculated as the ratio between the determined and the theoretical maximum concentration. The latter was obtained by dividing dose by theoretical circuit volume. Results Average drug recoveries at 180 min in three neonatal silicone membrane roller pump circuits were midazolam 0.62%, morphine 23.9%, fentanyl 0.35%, paracetamol 34.0%, cefazolin 84.3%, meropenem 82.9% and vancomycin 67.8%. There was a significant correlation between the lipophilicity of the drug expressed as log P and the extent of drug absorption, p < 0.001. The recovery of midazolam and fentanyl in centrifugal pump circuits with hollow-fibre membrane oxygenator was significantly higher compared to neonatal roller pump circuits with silicone membranes: midazolam 63.4 versus 0.62%, fentanyl 33.8 versus 0.35%, p < 0.001. Oxygenator size and used circuits do not significantly affect drug losses. Conclusions Significant absorption of drugs occurs in the ECMO circuit, correlating with increased lipophilicity of the drug. Centrifugal pump circuits with hollow-fibre membrane oxygenators show less absorption for all drugs, most pronounced for lipophilic drugs. These results suggest that pharmacokinetics and hence optimal doses of these drugs may be altered during ECMO.